What is the benefit of asprin in reducing colorectal cancer recurrence? Elizabeth Tracey reports
Update: 2025-10-20
Description
People who’ve had colorectal cancer and who have a mutation known as PI3 kinase benefit from taking asprin to prevent recurrence, a new study shows. William Nelson, director of the Kimmel Cancer Center at Johns Hopkins, describes the findings.
Nelson: There were recurrences in each group that got aspirin. In about 7.7% but if you had the hotspot mutation the recurrences were 14.1% with placebo if you had the other ones and it was 16.8% so there's a significant benefit or reduction in the chance for colorectal cancer to come back if you took aspirin. There were some adverse events 16.8% on aspirin and 11.6% on placebo bleeding or bruising. It does look like the science behind it seems reasonable, aspirin did the trick. :33
Nelson advocates for everyone with cancer to get a genetic analysis of their malignancy to determine the best treatments and long term prevention strategies. At Johns Hopkins, I’m Elizabeth Tracey.
Nelson: There were recurrences in each group that got aspirin. In about 7.7% but if you had the hotspot mutation the recurrences were 14.1% with placebo if you had the other ones and it was 16.8% so there's a significant benefit or reduction in the chance for colorectal cancer to come back if you took aspirin. There were some adverse events 16.8% on aspirin and 11.6% on placebo bleeding or bruising. It does look like the science behind it seems reasonable, aspirin did the trick. :33
Nelson advocates for everyone with cancer to get a genetic analysis of their malignancy to determine the best treatments and long term prevention strategies. At Johns Hopkins, I’m Elizabeth Tracey.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
